A B S T R A C T Fibrin formed in response to ancrod, reptilase, or thrombin was reduced by P-mercaptoethanol and examined by sodium dodecyl sulfate polyacrylamide gel electrophoresis. It was found that ancrod progressively and totally digested the a-chains of fibrin monomers at sites different than plasmin; however, further digestion of fibrin monomers by either reptilase or thrombin was not observed. Highly purified ancrod did not activate fibrin-stabilizing factor (FSF); however, the reptilase preparation used in these experiments, like thrombin, activated FSF and thereby promoted cross-link formation. Fibrin, formed by clotting purified human fibrinogen with ancrod, reptilase, or thrombin for increasing periods of time in the presence of plasminogen, was incubated with urokinase and observed for complete lysis. Fibrin formed by ancrod was strikingly more vulnerable to plasmin digestion than was fibrin formed by reptilase or thrombin. The lysis times for fibrin formed for 2 hr by ancrod, reptilase, or thrombin were 18, 89, and 120 min, respectively.
Received for publication 3 April 1972 and in revised form 18 July 1972. 1 Arvin is the registered trademark of Twyford Laboratories, Ltd., London. of the Malayan (Agkistrodon rhodostoma) and South American (Bothrops atrox) pit vipers, respectively (1, 2) . Both purified coagulants are known to cause a marked lowering of the plasma fibrinogen by converting it to fibrin which in turn, is assumed to be rapidly digested by plasmin before significant vascular occlusion and organ dysfunction occur (3) (4) (5) (6) (7) (8) (9) (10) . Of the two preparations, ancrod has been more extensively studied in humans, and to date, there appears to be very few thrombotic, hemorrhagic, or allergic complications associated with its use (5, 6, (11) (12) (13) (14) (15) (16) (17) . As a result of such observations, attention has been focused on these two venom enzymes for their potential usefulness in acute thromboembolic disorders. intravascular fibrin fornmation which in turn evokes an enhanced blood fibrinolytic state (4, 6, 12, 30) . Both the increased fibrinolysis and the reticuloendothelial system are thought to be important in the clearance of such intravascular fibrin (31) . Because increased clinical use is anticipated, studies aimed at defining or clarifying the mechanisms of action of these enzymes seemed essential.
In the studies which we wish to report here, polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate (SDS) has been used to study fibrin formed when ancrod, reptilase, or thrombin was added to purified human fibrinogen. This technique has also been used to determine if ancrod or reptilase activates highly purified FSF and plasmninogen. In addition, the degradation of ancrod-, reptilase-, and thrombin-formed fibrin by plasmin has been studied. Besides releasing fibrinopeptide A, it was found that ancrod, unlike reptilase, markedly degraded the a-chains of fibrin monomers and thereby significantly increased the susceptibility of such fibrin to digestion by plasmin. Neither enzyme appeared to have a direct proteolvtic effect on previously formed cross-linked fibrin.
METHODS
Idcagcnts. Human fibrinogen, fraction 1-2 (95% clottable), was prepared by the method of Blombdck and Blombalck from fresh frozen plasma (32) . After purification, this fibrinogen still contained sufficient FSF to yield fully crosslinked fibrin (33) . Human thrombin, kindly supplied by Dr. D. L. Aronson, Division of Biological Standards, National Institutes of Health, was dissolved in 0.05 M Tris * HC1 0.15 AI sodium chloride, pH 7.4, buffer (hereafter referred to as tris buffer) to give a concentration of 25 NIH U/ml and stored at 4'C. Purified human FSF was prepared as recently reported (34) and was dialyzed into 0.005 M TrisHCl-0.0001 sf EDTA, pH 7.5, buffer and then diluted to give an absorbance of 1.0 at 280 nm. Urea-treated fibrinogen was prepared as previously described (35) , except that the concentration of fibrinogen was 5 mg/ml in tris buffer. This solution was then stored at -200C. Human plasminogen was prepared according to the method of Deutsch and Mertz (36) . Plasminogen purified by this method showed a SA of 20 CTA U/absorbance U at 280 nm. After chromatography the protein was dialyzed extensively against distilled water to remove salt, lyophilyzed, and stored at -200C. In this preparation no autoactivation could be detected even after 1 yr as judged by SDS-gel electrophoresis of reduced plasminogen. For use in this study a 2.0 mg/ml plasminogen solution was prepared in tris buffer and used immediately as described below. Human urokinase (Calbiochem, San Diego, Calif.) was dissolved in tris buffer to give a final concentration of 460 Ploug U/ml and stored at -20'C.
In several studies freshly collected whole plasma was Ancrod treatment of completely cross-linked fibrin. Fibrin was prepared by the addition of purified human thrombin to purified human fibrinogen as described above. In all cases, calcium chloride was present and the samples were allowed to clot for 3 hr so that complete -y-dimerization and extensive a-polymerization occurred (33) . Following the addition of 15 ul of ancrod 1 or 5 ,ul of ancrod 3, to each of the 0.2-ml fibrin samples, the clot was loosened from the test tube wall and allowed to incubate for 0, 5, 15, 30, 60, 120, 240, 480 min, and 24 hr. The clots were then washed in a large volume of 0.15 M sodium chloride, blotted, and dissolved in 1.0 ml of 5 M urea-2% SDS-2% O-mercaptoethanol -0.01 MI sodium phosphate buffer, pH 7.15. After overnight incubation at room temperature, the samples were electrophoresed on SDS gels.
Formation of fibrin from plasma by thrombin, ancrod, and reptilase. 1-ml portions of citrated plasma or 1-ml portions of heparinized plasma were clotted by either 20 jd of purified thrombin, 40 Al of reptilase, 30 ,l of ancrod 1, 20 ,Iu of ancrod 2, or 5 A.l of ancrod 3, and allowed to stand for 4 hr at room temperature. During this time the heparinized plasma sample to which thrombin had been added did not clot. All other samples clotted in 3 min or less. Each fibrin clot was washed and blotted as described above and dissolved in 1.0 ml of 5 M urea-2%o SDS-2% P-mercaptoethanol, 0.01 sodium phosphate buffer, pH 7.15, and electrophoresed on SDS gels after overnight incubation at room temperature.
Incubation of plasininogen with thronibin, ancrod, reptilase, and urokinase. A 10 Al sample of the purified plasminogen solution was treated with either 50 ul of purified human thrombin, 50 ,l of reptilase, 50 ,ul ancrod 1, 50 ul of ancrod 2, 2% SDS-2%o p-mercaptoethanol. After overnight incubation at room temperature the samples were electrophoresed.
Inciibation of plasma FSF Zvvogen with thrombin, ancrod, or reptilasc. The putrescine-"C assay (37, 38) was used to determine if the two venom enzymes activated plasma FSF. In this test, the amount of putrescine-"C' (New England Nuclear, Boston, Mass.) incorporated into casein (Worthington Biochemical Corp., Freehold, N. J.) by activated FSF is quantitated. The assay was modified so that plasma FSF zymogen was preincubated with either thrombin, ancrod, or reptilase. 70 /4g of FSF in a volume of 200 IuI was incubated with either 4 U of thrombin, 2 U of ancrod 1, 2 U of ancrod 2, or 3 U of reptilase. The concentrations of thrombin, the ancrod preparations, and reptilase used in these studies were adjusted so that each gave identical clotting times when added to a standard fibrinogen solution. After incubation for 30 min, a portion of the preincubation mixture was assayed for FSF activation as originally described (37, 38) .
It has been shown that thrombin activates plasma FSF by cleaving a 4000 mol wt peptide from the a-chain of the zymogen (34) . Since this molecular weight change can be detected easily by SDS-gel electrophoresis, this method was also used to evaluate the effect of ancrod or reptilase on highly purified plasma FSF zymogen. Thus at 30 min and again at 120 min, 40-/il portions were removed from the preincubation mixtures and were added to 40 gtl of 9 Ai urea-2% SDS-2%o 6-mercaptoethanol in 0.01 Ai sodium phosphate buffer, pH 7.1, in order to stop the reaction and to prepare the samples for SDS-polyacrylamide gel electrophoresis.
Sutsceptibility of fibrin, formed by thrombin, ancrod, and reptilase to plasmin, degradation. Fibrin was prepared as described above using 0.2-ml portions of fibrinogen solution with either 20 /Al of purified thrombin, 25 1.d of reptilase, or 15 gl of ancrod 1. Both the thrombin and reptilase clots were prepared in the presence of calcium. In these experiments, calcium was not added to the ancrod-clotting mixtures since ancrod 1 catalyzes the formation of only noncross-linked fibrin whether or not calcium is present. All samples were clotted for 5, 15, 30, 60, 120, 240, and 480 min. In addition, soluble noncross-linked fibrin was prepared by clotting urea-treated fibrinogen with thrombin for 120 min in the absence of calcium. At the end of the different times, each fibrin clot was dislodged from the test tube wall as 20 pl of urokinase solution was added and the time required for complete clot lysis was recorded.
SDS-gel electrophoresis. Polyacrylamide gel electrophoresis was performed essentially as described previously (39, 40) . Throughout this study 7.5% gels were used and the gel tubes were 10 cm in length and 0.6 cm in diameter. Bromophenol blue was used as a marker in all cases. A load of approximately 25 jig of protein was applied to each gel. In order to calculate molecular weights, the following standards were used in each gel run (molecular weight in parentheses): phosphorylase A (92,500), transferrin (77,000), albumin (67,000), catalase (60,000), ovalbumin (43,000), pepsin (35,000), and chymotrypsinogen A (26,000).
RESULTS
Fibrin formation by ancrod and reptilase. Fig. 1 shows the effects of ancrod 1 on fibrinogen with time in the absence of calcium. The time course in Fig. 1 (42, 43) . Ancrod treatment of completely cross-linked fibrin. Completely cross-linked fibrin was prepared by the addition of human thrombin and calcium to fibrinogen containing contaminant FSF. These samples were then incubated with either ancrod 1 or ancrod 3. The results were the same for both preparations. Fig. 4 shows the SDS-gel electrophoretic patterns from the experiment performed with ancrod 3. It is apparent that a-polymer is not degraded by ancrod. The presence of the 38,000 and 33,000 mol wt a-chain cleavage products can be accounted for by the disappearance of the residual monomeric a-chains which were not incorporated into the a-polymer. Examination of 24-hr samples still revealed a-polymer to be present. but minimally diminished in intensity. This was due to slow fibrin degradation by trace amounts of contaminating plasmin (43) and was not due to ancrod digestion as recently suggested by other investigators (27) .
Formation of fibrin from plasma by ancrod and reptilase. Table I shows the clotting times for both heparin-ized and citrated plasma clotted by ancrod, reptilase, or thrombin. As previously reported, heparin has little or no effect on fibrin formation in response to reptilase or ancrod (19, 20) . Not only does heparin inhibit fibrin formation by thrombin, but it also prevents FSF activation by thrombin. Therefore the ability of ancrod or reptilase to activate plasma FSF can be tested in heparinized plasma. The SDS-gel patterns of fibrin obtained by clotting heparinized plasma with ancrod or reptilase are shown in Fig. 5 . At the concentration used, thrombin did not induce clotting of the heparinized plasma even after 8 hr and therefore no gel is shown. As can be seen all ancrod preparations degraded a-chains in heparinized plasma. Most notably, neither y-dimer nor a-polymer formation was catalyzed by ancrod 1. However both ancrod 2 and reptilase clearly promoted y-dimer and a-polymer formation in the presence of heparin. Ancrod 3 catalyzed only a slight amount of 'y-dimer formation.
Incubation of plasminogen with thrombin, ancrod, reptilase, and urokinase. Since indirect evidence suggested that the venom enzymes do not activate plasminogen (6, 14, 29) , the effect of ancrod and reptilase on purified human plasminogen was examined. Fig. 6 shows the reduced SDS-gel electrophoretic patterns for plasminogen alone, plasminogen incubated with either thrombin, ancrod, or reptilase and plasmin formed by the action of urokinase on plasminogen. The plasminogen sample incubated with urokinase clearly shows that plasminogen activation has occurred as evidenced by the appearance of the heavy and light chains of plasmin (44) . However when purified plasminogen was incubated with thrombin, ancrod, or reptilase, plasminogen activation did not occur.
Incubation of plasma FSF with thrombin, ancrod, and reptilase. Fig. 7 shows the SDS-gel patterns of reduced samples of plasma FSF after incubation with the various enzymes. As previously reported (34), gel, a shows the overlap of the a and b-chains of reduced plasma FSF zymogen. Gel b shows that with activation by thrombin the a-chain decreases in molecular weight and is then designated a'-chain. Gel c clearly shows that ancrod 1 does not activate plasma FSF. Gel d shows proximately four to six such potential cross-links sites (46) . Initially a pair of cross-links are rapidly formed between Y-chains of different fibrin monomers to give rise to -t-dimer formation; more slowly, several a-chains of different fibrin monomers are cross-linked to give rise to a-polymer formation (33) . As a-polymerization progresses, the fibrin becomes completely insoluble in the above solvents and is then termed fully cross-linked fibrin. Unlike thrombin, ancrod and reptilase are reported to cleave only fibrinopeptide A from fibrinogen; in addition ancrod partially degrades fibrinopeptide A (22) (23) (24) .
Neither cleaves fibrinopeptide B, but despite this, fibrin formation still occurs rapidly. In vivo such fibrin is rapidly cleared and this has been attributed to lysis by plasmin (30, 47) , since no further direct proteolytic effect of ancrod on fibrin could be demonstrated (22, 24, 29) , and to phagocytosis of fibrin by the reticuloendothelial system (31) . However, it recently has been shown that ancrod itself definitely degrades the a-chains of monomeric fibrin to yield approximately 38,000 and 33,000 mol wt cleavage products (2628), the latter of which appears to undergo further degradation by ancrod. None of these cleavage products were seen during the degradation of either fibrinogen or fibrin by plasmin (42, 43) . Our data clearly indicate that in the presence of FSF, fibrin formed by ancrod is markedly more susceptible to plasmin degradation than fibrin formed by thrombin. This usually has been attributed solely to the fact that ancrod-formed fibrin is noncross-linked (24, 29, 47) , since it has been shown that urea-soluble, noncross-linked clots are less resistant to lysis than crosslinked clots (48, 49) . In accord with these observations, results shown in Fig. 8 clearly demonstrate that by 2 hr, cross-linked fibrin has developed maximal resistance to lysis and -it is at this time that a-polymerization is essentially complete (33) . As recently suggested (35) , it appears that a-polymer formation makes fibrin resistant to plasmin degradation. Although previously hypothesized (1, 14, 50) , the possibility than ancrod itself significantly degraded fibrin monomers was not supported by experimental evidence and was discounted in one study (29) . In Fig. 8 , the time at which ancrod-formed fibrin was maximally susceptible to lysis by plasmin correlated well with the cleavage of a-chains by ancrod as shown in the SDS-gel electrophoretic patterns of Fig. 1 . In view of the observation that ancrod extensively degrades the a-chains of fibrin monomers and does not activate FSF, it is of interest that the elastic modulus of thrombin-formed, noncross-linked fibrin, (aftY)2, is about twice that of ancrod-formed fibrin (47) which likewise is noncross-linked and in addition, must contain some fraction of intact a-chains. Thus its subunit formula might be written as [(a/lx(B) Y]2, where x is some integer greater than one and the value of a/x is dependent on the duration of fibrin formation in response to ancrod. It is therefore suggested that the degradation of the a-chains in ancrod-formed fibrin accounts for its having a reduced elastic modulus. Our demonstration that ancrod-formed fibrin, which in the case of ancrod 1 is noncross-linked and contains degraded a-chains, is markedly susceptible to lysis has implications to the clinical use of these enzymes. It is suggested that the use of ancrod preparations which do not promote fibrin crosslinking is preferable, since noncross-liked fibrin is more susceptible to lysis than cross-linked fibrin. It would also appear that ancrod would be preferable to reptilase for use in vivo since, unlike the reptilase preparation, highly purified ancrod (ancrod 1) itself partially degrades fibrin monomers and does not promote their cross-linking. Thus the in vivo removal of fibrin formed in response to ancrod would be maximized.
The data shown in Fig. 6 emphasize that the effect of ancrod on a-chains is not due to plasminogen activation by ancrod. Moreover, as mentioned earlier, the degradation products by ancrod differ in molecular weight from those seen when plasmin degrades fibrinogen or fibrin (42, 43) . Some preparations of ancrod obviously contain a contaminant proteolytic enzyme which is capable of activating FSF and which, unlike thrombin, is not inhibited by heparin. Such a contaminant was present in ancrod 2 but on further purification of this preparation to ancrod 3, most of this activity was removed. Interestingly, ancrod 1, which did not cause FSF activation in the present study, has been the preparation used in most of the clinical trials to date.
It has recently been reported (2) Fig. 3 can be attributed to the effect of plasmin rather than reptilase, since they have mobilities identical with those products resulting from the digestion of fibrinogen by plasmin alone. Thus, it was not possible to confirm the data of Mattock and Esnouf (27) who suggested that reptilase, like ancrod, cleaved fibrin to yield a 39,000 mol wt species. Under the conditions employed in this present study, reptilase-formed fibrin showed only a small change in susceptibility to lysis with increased exposure to reptilase. Of particular note, the initial fibrin lysis time was not greatly different from that seen for thrombin clots.
While the work of Kwaan and Barlow (52, 53) (42) , no a-polymerization would occur and the lysis times for reptilase-formed fibrin would approximate those of ancrod-formed fibrin. Our present studies do not clarify the in vivo mechanisms of reptilase therapy; however, our data clearly show that reptilase activates FSF and in the presence of calcium promotes cross-linked fibrin formation which is in accord with the observations of other investigators (25) . Thus, it would seem that reptilase-formed fibrin in the microcirculation would be fully cross-linked and hence very similar to thrombin clots formed during diffuse intravascular coagulation except that, unlike thrombin, reptilase does not appear to induce platelet interactions (10) . Moreover, our data indicate that despite a slight trend towards increased susceptibility to lysis with longer duration of clotting, reptilase clots are much more resistant to lysis than are ancrod clots.
On the basis of our data and results from other studies, it is possible to postulate the following sequence of events to account for the anticoagulant effect of ancrod in vivo: (a) the administration of ancrod results in the formation of fibrin clots in the microcirculation, particularly in the kidney, lungs, liver, and bone marrow (54); (b) these clots, however, contain noncross-linked fibrin and furthermore become defective as the a-chains continue to be significantly degraded by ancrod; (c) the activation of plasminogen to plasmin occurs in a manner analogous to that observed when intravascular clotting occurs as a result of thrombin generation (12, 30, 55); (d) the resultant high level of plasmin then digests ancrod-formed fibrin at a much more rapid rate than thrombin-formed fibrin, and this can be attributed to the fact that such fibrin is noncross-linked and in addition, has already been significantly degraded by ancrod; (e) the generation of fibrin split products as well as the fibrinogenopenia produces a hypocoagulable state (56, 57) .
In general, the results of clinical studies support these mechanisms (6, 14) . In such studies, patients receiving ancrod showed a marked decrease in plasminogen concentration, which often approached zero after about 10 hr from the onset of ancrod administration. Also at this time, these investigators found that fibrin degradation products had usually reached a peak value. While the mechanism by which the fibrinolytic system becomes activated is not understood, it is clear that ancrod does not activate plasminogen as has been shown in this study by direct observations of ancrod action on purified plasminogen. Despite what mechanism ;may be invoked to explain the rapid activation of plasminogen to plasmin during intravascular clotting, it is apparent that ancrod clots are strikingly susceptible to plasmin degradation as shown in Fig. 8 . Besides digestion by plasmin, phagocytosis of fibrin by the reticuiloelndothelial system represents a second important method by which fibrin is removed from the microcirculation (31). However whether or not the defective, noncross-linked fibrin formed by ancrod is more susceptible to phagocytosis by the reticuloendothelial system is conjectural and must await further study.
